Thursday, 28 March 2024
Genscript Biotech Corporation
12:26 | 5/1/18
Geneva Journal
Investors may be interested in viewing the Gross Margin score on shares of Genscript Biotech Corporation (SEHK:1548). The name currently has a score of 50.00000.
more»
16:56 | 4/1/18
Trion Journal
Shares of Genscript Biotech Corporation (1548.HK) have seen the needle move -8.58% or -2.30 in the most recent session. The HKSE listed company saw a recent bid of $24.50 on 49184665 volume.
more»
02:18 | 4/1/18
Union Trade Journal
Genscript Biotech Corporation (SEHK:1548) has a current EV or Enterprise Value of 4601144. The EV displays how the market assigns value to a firm as a whole.
more»
12:48 | 3/1/18
Simply Wall St
Stocks with market capitalization between $2B and $10B, such as Genscript Biotech Corporation (SEHK:1548) with a size of HK$36.61B, do not attract as much attention from the investing community as do the small-caps and large-caps.
more»
22:45 | 28/12/17
Aiken Advocate
In the latest session, Genscript Biotech Corporation (1548.HK) moved -1.70%, touching a recent bid of 25.10. Current price levels place the shares above the rising trendline.
more»
01:22 | 28/12/17
PR Newswire
PISCATAWAY, N.J., Dec. 27, 2017 /PRNewswire/ -- GenScript® Biotech Corp., the leading global provider of gene synthesis services, announced today that it and GenScript USA Holding Inc., its wholly owned subsidiary, have entered into an agreement to ...
more»
01:56 | 26/12/17
Business Review
Genscript Biotech Corporation (1548.HK) have climbed higher in consecutive sessions revealing positive upward momentum over the past week.
more»
06:26 | 25/12/17
The Pharma Letter
In a move that takes it into the fast expanding chimeric antigen receptor (CAR) T-cell space, in which it has so far been conspicuously absent, Janssen Biotech, a subsidiary of US healthcare giant Johnson & Johnson (NYSE: JNJ), announced a licensing ...
more»
J&J's Janssen in CAR-T Deal, Priority Review for Apalutamide: J&J's Janssen Biotech has inked a worldwide collaboration and license agreement with Legend Biotech USA Inc. and Legend Biotech Ireland Limited, subsidiaries of Genscript Biotech Corporation ...
more»
22:45 | 22/12/17
PharmaTimes
... percent cost-sharing/profit-split arrangement. "Despite significant advances, multiple myeloma remains an incurable disease for most patients, creating the need for additional, highly active options.
more»
Code | Last | Change |
COMP | 10,321 | 328 | | 3.08% |
DJI | 29,635 | 404 | | 1.34% |
SP500 | 3,583 | 87 | | 2.37% |
DAX | 12,438 | 82 | | 0.67% |
FTSE | 7,488 | 5 | | 0.07% |
NI225 | 22,420 | 408 | | 1.86% |
TWI | 67.27 | 0.00 | | 0.00% |